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Regulatory T cells (Tregs) play an important role by controlling allergic inflammation of 
airways. Recently, it has been shown that statins have immunomodulatory properties, 
probably mediated by their effects on Tregs. Therefore, we evaluated the in vivo effect of 
atorvastatin (ATV) on Tregs and its association with the inflammatory process in a model 
of allergic asthma. BALB/c mice were sensitized with ovalbumin (OVA) and then chal-
lenged with intranasal OVA. ATV (40 mg/kg) was delivered by daily intraperitoneal injec-
tion for 7 or 15 days before each OVA challenge. ATV treatment for 7 days increased the 
frequency of Tregs in mediastinal lymph nodes (MLN) and the interleukin (IL)-10 in lungs. 
After 15  days of treatment, ATV increased the percentage of glucocorticoid-induced 
tumor necrosis factor receptor-related protein (GITR+) and programmed cell death 
protein 1 (PD-1+) Tregs in the lung, without enhancing their suppressive activity, but also 
increased the percentage of conventional T cells expressing GITR+, PD1+, and OX-40 
(tumor necrosis factor receptor superfamily member 4). Although no significant changes 
were observed in the number of inflammatory cells in the bronchoalveolar lavage (BAL), 
OVA-specific immunoglobulin E in the serum, and type 2 helper (Th2) cytokines in the 
lungs, there was a significant decrease of peribronchial inflammation that negatively 
correlated with the Tregs in MLN and the concentration of IL-10 in the lung. These results 
Abbreviations: Treg, regulatory T cells; ATV, atorvastatin; OVA, ovalbumin; MLN, mediastinal lymph nodes; IgE, immu-
noglobulin E; GITR, glucocorticoid-induced tumor-necrosis-factor-receptor-related protein; PD-1, programmed cell death 
protein 1; OX40, tumor necrosis factor receptor superfamily member 4; BAL, bronchoalveolar lavage; Th2, type 2 helper cells.
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inTrODUcTiOn
Allergic asthma is a highly complex chronic inflammatory dis-
ease of the airways. Since it is estimated that around 235 million 
people suffer from asthma, one of the objectives of the World 
Health Organization is to identify cost-effective interventions to 
reduce the morbidity and mortality related to this disease (1). 
Although immunopathology of asthma is heterogeneous, one 
of the first events that defines the initiation and perpetuation of 
chronic inflammation during allergic asthma is the differentia-
tion of CD4+ T cells toward a type 2 helper cells (Th2) profile. 
Remarkably, these cells produce cytokines such as interleukin 
(IL)-5, which mediates the development and recruitment of 
eosinophils to the airways (2), and IL-4 and IL-13, which promote 
isotype switching to immunoglobulin E (IgE) (3). In addition, 
cells of the innate immunity, such as mast cells, type 2 innate 
lymphoid cells, and basophils, and cells of adaptive immunity, 
such as B cells, Th17 cells, and Th1 T cells, act together with 
epithelial cells to cause airway remodeling, leading to bronchial 
hyperresponsiveness, airway narrowing, edema and mucous 
hypersecretion, and structural changes characteristic of allergic 
asthma (4, 5). On the contrary, regulatory T cells (Tregs) consti-
tute a subpopulation of CD4+ T cells that has been involved in 
controlling the magnitude of the immune response against envi-
ronmental antigens during allergic asthma (6). Tregs express the 
transcription factor forkhead box P3 (FOXP3), which is critical 
for their development and function (7). During allergic asthma, 
Tregs seem to play a beneficial role by inhibiting Th2 responses 
and regulating B-cell antibody production, mainly through the 
secretion of IL-10 and transforming growth factor beta (TGF-β) 
(8). Likewise, Tregs through contact-dependent mechanisms 
inhibit mast cell degranulation through OX40-OX40L (tumor 
necrosis factor receptor superfamily member 4) (9). However, 
the role of other surface molecules mediating suppressive func-
tion in allergic asthma is more controversial, since it has been 
demonstrated that programmed cell death protein 1 (PD-1) and 
glucocorticoid-induced tumor necrosis factor receptor-related 
protein (GITR) could have a proasthmatic role (10, 11).
Currently, the main treatment for allergic asthma is glucocor-
ticosteroids, which inhibit the expression of multiple inflamma-
tory genes; however, their prolonged use may have adverse side 
effects (12) and around 5 to 10% of patients develop resistance 
to glucocorticoids (13). The search and development of alterna-
tive or complementary therapies, with a good safety profile, 
easy administration, and immunomodulatory potential, would 
constitute an attractive strategy in the control of immunopathol-
ogy of asthma. Statins are drugs widely used to lower lipid levels, 
but they also possess cholesterol-independent or “pleiotropic” 
effects, among which are their potent immunomodulatory and 
anti-inflammatory action (14). Regarding immunomodulatory 
actions, recently, we and others have demonstrated that statins 
can have immunomodulatory actions mediated by their direct 
effect on Tregs, increasing the size of this population, their 
phenotype or function in the steady state (15), and under inflam-
matory conditions (16–18). Moreover, although statins possess 
immunomodulatory effects in murine models of ovalbumin 
(OVA)-induced asthma, such as the reduction of leukocytes in 
bronchoalveolar lavage (BAL) (19–21), OVA-specific IgE level 
(20), Th2-cytokine secretion (19–21), bronchial (peribronchial 
and perivascular) inflammation (19), and mucus production 
(21), it is unknown whether these beneficial effects are associ-
ated with the induction and/or activation of Tregs. Therefore, we 
hypothesized that pharmacologic treatment with atorvastatin 
(ATV) could contribute to reduce the inflammatory response 
of allergic asthma in a murine model by modulating the size, 
phenotype, or function of the Treg population. We found that 
ATV treatment increased Treg population but decreased the 
transcriptional expression of Th2 cytokines profile in mediastinal 
lymph nodes (MLN) and increased IL-10 levels in the lung, sug-
gesting an immunomodulatory role of ATV, possibly mediated 




The 8- to 10-week-old pathogen-free male BALB/c mice 
weighing 20–25  g were provided by the Sede de Investigación 
Universitaria vivarium of the University of Antioquia. They were 
maintained in laminar flow cage racks with a 12-hour light/dark 
cycle and ad libitum access to food and water. All experimental 
procedures were approved by the Ethics Committee for Animal 
Experimentation of the University of Antioquia.
experimental Design
OVA Sensitization
Male mice were divided into three groups with around five mice 
per group in each of three replicates. The sensitized (S) and 
ATV-treated (S +  ATV) groups were obtained by using mice 
sensitizing with 2 µg OVA (Sigma-Aldrich, St. Louis, MO, USA) 
emulsified in 200 µL containing 2.6 mg/mL aluminum hydroxide 
(Sigma-Aldrich) by intraperitoneal (i.p.) injection on days 0 and 
14 (22). The animals were subjected to two different protocols of 
OVA challenge and ATV treatment.
27 Days Model
On days 20 and 24, the mice were challenged intranasally (i.n.) 
with 10  µg OVA dissolved in 50  µL phosphate-buffered saline 
suggest that ATV has an immunomodulatory role possibly mediated by their effects on 
Tregs, which could contribute to the control of inflammation during allergic asthma. 
Further studies are necessary to elucidate the contribution of Treg to immunomodulatory 
action of statins in the context of allergic asthma.
Keywords: regulatory T cells, il-10, asthma, ovalbumin, atorvastatin
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(PBS) (23). The S +  ATV group received an i.p. injection of 
40 mg/kg ATV (Biogen Laboratory, Bogotá, Colombia) dissolved 
in PBS, which was administered 30 min before the OVA challenge 
from day 20 to 26. On day 27, the mice were sacrificed.
35 Days Model
We performed four OVA challenges on days 20, 24, 28, and 32. 
Treatment with ATV was also performed daily, from day 20 to 
34, for a total of 15 doses. On day 35, the mice were sacrificed 
(Figures S1A,B in Supplementary Material).
In addition, we included mice that were not sensitized (NS) 
but received the challenges with OVA according to each model, as 
control groups. In some experiments, we included ATV-treated 
NS mice.
Determination of OVa-specific serum ige 
levels
Blood samples were collected immediately after anesthesia 
by cardiac puncture. Serum samples were obtained for the 
quantification of OVA-specific IgE antibodies by enzyme-linked 
immunosorbent assay (ELISA). Briefly, 96-well plates were 
coated with anti-mouse IgE antibodies overnight at 4°C (BD 
PharMingen, San Diego, CA, USA). ELISA plates were blocked 
for 2 h with 10% fetal bovine serum (FBS; Gibco-Thermo Fisher 
Scientific, USA) and 0.05% Tween 20 (AMRESCO, Solon, OH, 
USA) dissolved in PBS at room temperature. Then, 50  µL of 
serum was serially diluted fivefold in PBS, added to the wells, 
and incubated overnight at 4°C. Biotinylated OVA was added the 
following day, and the streptavidin/alkaline phosphatase complex 
(DAKO, Glostrup, Denmark) and the p-nitrophenylphosphate 
substrate (Sigma-Aldrich) were added and incubated for 20 min. 
To detect the reaction, the optical density was measured using 
an ELISA detector at 405 nm. Serum titers are expressed as the 
reciprocal value of the maximal serum dilution with a positive 
result defined as the optical density value higher than twofold 
over the background value of a serum sample at1:5 dilution from 
a non-sensitized mouse (22).
collection and analysis of 
Bronchoalveolar lavage
Immediately after blood collection, the thoracic cavity was 
opened by careful dissection. The trachea was exposed, and a 
small transverse incision was made just below the larynx, where 
a cannula was inserted. Then, BAL was collected by lavaging the 
lungs three times with 1 mL PBS. BAL was resuspended, and the 
total viable cell numbers were determined by trypan blue exclu-
sion using a hemocytometer. For the preparation of cytospins, 
BAL was centrifuged at 600 × g for 10 min using a Cytospin III 
(Shandon, Pittsburg, PA, USA). These preparations were stained 
with colorant Wright, and differential cell counting of 100 cells 
was performed using standard morphological criteria.
cytokine levels in lung Tissues
Left lungs were macerated and filtered through a nylon mesh 
(70 µm; Spectrum Labs, Rancho Dominguez, CA, USA) in 2 mL 
PBS and centrifuged at 1,500 rpm at 4°C for 10 min. Supernatants 
were collected, and the IL-4, IL-5, and IL-10 levels were evaluated 
using the kit Mouse OptEIA (BD PharMingen) and IL-13 levels 
using the Mouse DuoSet ELISA (R&D Systems Inc., McKinley, 
MN, USA) according to the manufacturer’s instructions. The 
concentration of the cytokines was determined through standard 
curves generated using different concentrations of recombinant 
cytokines. The limit of detection for each cytokine was as follows: 
IL-4: 7.8 pg/mL, IL-5: 15.6 pg/mL, IL-13: 62.5 pg/mL, and IL-10: 
31.3 pg/mL.
lung histology
After BAL sampling was completed, the right lungs were 
removed from the thoracic cavity by careful dissection and fixed 
in buffered 10% formalin. After fixation, the lungs were sectioned 
and embedded in paraffin, and 4-µm sections were cut using a 
Leica microtome (Leica Microsystems, Nussloch, Germany). 
The sections were assigned a random code to blind the examiner 
identifying each specimen. Tissue sections were then stained 
with hematoxylin and eosin (H&E; Sigma-Aldrich). The degree 
of inflammation was quantified following a scale modified 
from that of Cao et al. (24): 0, normal; 1, few cells; 2, a ring of 
inflammatory cells 1 cell layer deep; 3, a ring of inflammatory 
cells 2–4 cells deep; 4, a ring of inflammatory cells 5–6 cells deep; 
and 5, a ring of inflammatory cells of >6 cells deep. To evaluate 
mucus production, tissue sections were stained with Periodic 
acid–Schiff (PAS). The number of goblet cells was determined 
using the formula: (PAS-positive cells/total cells) × 100. Mucus 
production was determined according to the following scale: 0: 
0%; 1: ≤15%; 2: 16–30%; 3: 31–45%; 4: 46–60%; and 5: >60% 
goblet cells (24). The scores of the pulmonary inflammation and 
mucus production were performed on a microscope (Nikon 
Labophot 2; Melville, NY, USA) at a magnification of ×400 by 
examining at least eight representative fields as analyzed by a 
blinded pathologist.
collection of lung and Mln cells and 
Flow cytometry
Mediastinal lymph nodes were removed and processed simi-
larly to lung as described in Section “Cytokine Levels in Lung 
Tissues.” The cells were collected, and the remaining erythro-
cytes of the left lung were lysed (lysis buffer, eBioscience, San 
Diego, CA, USA) according to the manufacturer’s instructions. 
Single-cell suspensions from MLN and lung tissues were 
resuspended at 1 × 106 cells/mL. The cells were labeled with the 
following monoclonal fluorochrome-conjugated antibodies: 
anti-CD3-Brilliant Violet 510 (clone 17  A2, BioLegend, San 
Diego, CA, USA), anti-CD4-eFluor 450 (clone RM4-5, eBiosci-
ence), anti-CD25-APC (clone PC61, BD Pharmigen), anti-OX-
40-PE (clone OX-86, eBioscience), anti-PD-1-APC-eFluor 780 
(clone J43, eBioscience), and anti-GITR-PE-Cyanine 7 (clone 
DTLA-1, eBioscience) for 30 min at 4°C in the dark. The cells 
were then washed in PBS and incubated with a fixation buffer 
(eBioscience) for 30  min at 4°C in the dark. After washing, 
the cells were resuspended in permeabilization solution 1× 
(eBioscience) and stained with anti-FOXP3-Alexa Fluor 488 
(clone FJK-16s, eBioscience) for 30 min at 4°C in the dark. Flow 
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cytometry was performed on a FacsCANTO II TM (BD, San 
Diego, CA, USA). At least 100,000 events were analyzed with 
FlowJo (Tree Star) or FACSDiva (BD Biosciences) software. 
Gating strategy is indicated in Figure S2 in Supplementary 
Material.
Quantitation of gene expression Using 
real-time Polymerase chain reaction 
(Pcr)
Total RNA was purified from cell suspensions of MLN using a 
commercial kit (RNeasy mini kit, Qiagen, Hilden, Germany) 
according to the manufacturer’s instructions. The RNA was 
retrotranscribed to cDNA using random hexamers and 
the Revertaid™ H Minus First Strand cDNA Synthesis Kit 
(Fermentas, Glen Burnie, MD, USA). PCRs were performed 
in a final volume of 15  µL using the Maxima SYBR Green 
qPCR master mix kit (Fermentas). Specific primers and the 
PCR conditions are shown in Table S1 in Supplementary 
Material. Real-time reverse transcription PCR was performed 
in a CFX96™ Real-Time PCR Detection System (Bio-Rad, 
Hercules, CA, USA). The data are expressed as relative units 
of each gene normalized against the constitutive gene (β-actin) 
using the formula 1.8−[∆Ct], where 1.8 corresponds to the mean 
PCR efficiency of 80% (25).
In Vitro suppression assay
CD4+ T cells were obtained from the splenocytes and purified 
using the CD4+CD25+ regulatory T Cell Isolation Kit (Miltenyi 
Biotec, Auburn, CA, USA), following the manufacturer’s instruc-
tions. CD4+CD25+ Tregs were cultured in 96-well round-bottom 
plates and preactivated with plate-bound anti-CD3 (2.5  µg/ml, 
145-2C11, eBioscience) and soluble anti-CD28 (2.5 µg/mL, 37.51, 
eBioscience) antibodies in RPMI 1640 medium (Sigma-Aldrich) 
supplemented with 10% FBS, 100  U/mL IL-2 obtained from 
the Institutes of Health, AIDS Research and Reference Reagent 
Program (Bethesda, MD, USA), 100 U/ml penicillin, and 100 µg/
mL streptomycin (Sigma-Aldrich) for 48 h at 37°C with 5% CO2. 
The Tregs were then co-cultured with CD4+CD25− conventional 
T cells (Tcon) labeled with 1.25  µM carboxyfluorescein diac-
etatesuccinimidyl ester (CFSE, Invitrogen) and stimulated as 
indicated earlier at a ratio of 1:1 in 96-well plates. Co-cultures 
were incubated for 72  h at 37°C with 5% CO2. Cell division 
was measured by CFSE dilution through flow cytometry. The 
percentage of suppression was calculated as follows: (100  −   
(% proliferation of Tcon in the presence of Treg/% proliferation 
of Tcon alone) × 100).
statistical analysis
The data were analyzed by Student’s t-test and are expressed 
as the mean  ±  SD. When the data were not normally dis-
tributed, the Mann–Whitney test was applied and the results 
are expressed as the median  ±  interquartile range. The 
program GraphPad Prism Version 6 was used for the analysis 
(San Diego, CA, USA). Correlation analyzes were performed 
using the Spearman coefficient. A value of p < 0.05 was consid-
ered statistically significant.
resUlTs
aTV increases the Frequency of Tregs in 
Mlns
Since a beneficial role of Tregs has been demonstrated during 
asthma (26–28), and because ATV treatment increases Treg 
populations, we evaluated the immunomodulatory effect of ATV 
treatment on Tregs in a murine model of allergic inflammation 
of the airways. As shown in Figure  1A, treatment with ATV 
(40 mg/kg, i.p.) for 7 days significantly increased the frequency 
of CD25+FOXP3+ Tregs in MLN. No significant difference 
was observed between groups in the lung tissue (Figure  1B). 
Interestingly, ATV treatment also increased the frequency of Treg 
in MLN and lung in non-sensitized mice compared to untreated 
non-sensitized animals (Figure S3 in Supplementary Material).
long-lasting Treatment with aTV 
Modulates the Phenotype of the Treg 
Population
Since differential expression of surface molecules on Tregs can be 
associated with their regulatory function, we examined whether 
ATV could modulate the phenotype of Tregs during allergic 
inflammation of the airways. It was observed that sensitiza-
tion per  se increased the frequency of Tregs expressing OX-40 
and PD-1 molecules in lung compared to non-sensitized mice 
(Figures 2A,B). Although ATV treatment for 7 days did not affect 
the expression of OX-40, PD-1, or GITR on Tregs in both MLN 
and lung of sensitized mice compared to the untreated sensitized 
mice (Figures 2A–C), ATV upregulated the percentage of Treg 
expressing OX-40 and PD-1 in lung of non-sensitized mice 
(Figure S4 in Supplementary Material).
Considering that changes in the phenotype of Tregs could 
depend on time (15), we increased the number of doses of ATV 
from 7 to 15 and observed a significantly increased frequency 
of Tregs expressing GITR and PD-1 in the target tissue (lung) 
compared to untreated sensitized mice (Figures  2D,E). Also, 
upregulation of the OX-40, PD-1, and GITR molecules was 
observed on conventional CD4+ T cells (FOXP3- population) 
after ATV treatment (Figure S5 in Supplementary Material). 
In spite of increasing the expression of suppression markers on 
Tregs, the suppressive activity after 15 days of ATV treatment was 
not enhanced, as shown in the classical in vitro suppression assay 
(Figure 2F; Figure S6 in Supplementary Material).
aTV increases Foxp3 and TGF-β 
Messenger rna in Mln and il-10 levels 
in the lung
To further confirm the in vivo effect of ATV on the Tregs under 
allergic inflammatory conditions, we evaluated the transcrip-
tional expression of some genes associated with Treg function 
in MLN. Administration of ATV led to a significant increase 
in Foxp3 and TGF-β mRNA expression in sensitized animals 
compared to sensitized but untreated mice (Figures  3A,B). 
Sensitization per  se induced a significant increase in IL-10 and 
indoleamine-pyrrole-2, 3-dioxygenase enzyme (IDO) mRNA 
FigUre 1 | atorvastatin (aTV) increases the frequency of cD4+FOXP3+cD25+ regulatory T cells (Tregs) in a murine model of allergic asthma.  
(a) Representative flow cytometry dot plot of CD25+FOXP3+ Tregs gated on CD4+ of mediastinal lymph nodes (MLN) from non-sensitized (NS●), sensitized (S▲), 
and sensitized treated with ATV (S + ATV▾) mice evaluated at day 27. (B) Frequency of CD4+CD25+FOXP3+ Treg in MLN and lung in the study groups. Data are 
shown as mean ± SD (n = 14–17 mice per group pooled from three independent experiments, *p < 0.05 Student’s t-test).
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level (Figures  3C,D). However, ATV treatment had no effect 
on the transcriptional level of IL-10, IDO, or IL-35, the latter 
composed of two subunits: IL-12A and EBI-3 (Figures  3C–F, 
respectively).
Because IL-10 is involved in controlling allergic asthma (8, 
29) and its production could be promoted by statins (30, 31), we 
assessed the IL-10 concentration in lung homogenates. Although 
sensitization increased the level of IL-10 compared to that of non-
sensitized mice (Figure  3G), ATV treatment further boosted 
IL-10 production (Figure 3G).
aTV Therapy Modulates the inflammatory 
Process in sensitized animals
Previous investigations have demonstrated the anti-inflammatory 
activity of statins during allergic asthma (19, 20, 32). Therefore, 
we examined the effects of ATV on the influx of inflammatory 
cells into BAL in OVA-sensitized mice. As expected, there was a 
significant increase in the number of inflammatory cells in sensi-
tized versus non-sensitized mice (Figure 4A). Similarly, sensitiza-
tion induced a significant increase in eosinophil count compared 
to non-sensitized animals (Figure 4B). However, in our model, 
ATV treatment did not reverse cell infiltration or eosinophil 
count induced by sensitization (Figures 4A,B). As expected, the 
sensitization process also increased the serum OVA-specific IgE 
levels and the IL-4, IL-5, and IL-13 concentrations in lung super-
natants compared to control mice (Figures 4C–F, respectively). 
However, ATV treatment did not significantly modify the serum 
IgE levels or Th2 cytokines in the lung compared with sensitized 
mice (Figures 4C–F).
We next examined the lung tissue sections stained with H&E 
and observed that OVA-sensitized mice displayed extensive 
inflammatory infiltrates in peribronchial areas compared to non-
sensitized animals (Figures 5A,B). Interestingly, ATV treatment 
for 7 and 15 days reduced the score value of inflammation in the 
peribronchial region from 5 in ATV-untreated sensitized mice 
to 4 and 3 in those treated, respectively (Figure 5B). Although 
mucus production was observed in sensitized mice compared 
to non-sensitized mice, ATV treatment did not modulate this 
parameter (Figure 5C).
The mRNA expression level of Th2 cytokines in MLN was then 
compared: it showed that the sensitization process also increased 
mRNA expression of all evaluated cytokines compared to that in 
non-sensitized mice, whereas that ATV treatment significantly 
decreased the mRNA of IL-4 and IL-13 (Figures 5D,E). A trend 
toward decrease was also observed in the level of IL-5 after ATV 
treatment (Figure 5F).
FigUre 2 | long-lasting atorvastatin (aTV) treatment modulates phenotype of regulatory T cells (Tregs) in a murine model of asthma. The frequency of 
(a) CD4+CD25+FOXP3+OX40+ Tregs, (B) CD4+CD25+FOXP3+PD1+ Tregs, and (c) CD4+CD25+FOXP3+GITR+ Tregs was measured by flow cytometry in mediastinal 
lymph nodes and lung on day 27 in non-sensitized (NS●), sensitized (S▲), and sensitized treated with ATV (S + ATV▾) mice. The frequency of (D) 
CD4+CD25+FOXP3+GITR+ Tregs and (e) CD4+CD25+FOXP3+PD1+ Tregs was measured by flow cytometry in both tissues in the study groups at day 35.  
(F) Percentage of suppression of conventional T cells proliferation in the presence of Tregs from ATV-treated or untreated sensitized mice (n = 4 mice per group). 
Data from (a–c) are shown as mean ± SD (n = 12–17 mice per group pooled from three independent experiments, *p < 0.05 Student’s t-test). Data from (D–F) are 
shown as median and interquartile range (n = 6–7 mice per group from one experiment, *p < 0.05, ***p < 0.001 Mann–Whitney test).
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The induction of Tregs correlates with a 
Decrease of Peribronchial inflammation
To determine whether Tregs contribute to the control of inflam-
mation in lung tissue, we correlated the frequency of Tregs with 
several inflammatory parameters. Interestingly, a negative cor-
relation between peribronchial inflammation and (i) frequency 
of Tregs in MLN (Figure 6A), (ii) frequency of Tregs expressing 
GITR in MLN (Figure 6B), and (iii) concentration of IL-10 in 
the lung (Figure 6C) was observed. Moreover, the IL-10 protein 
concentration in the lung was positively correlated with the 
frequency of Tregs in the MLN (Figure 6D).
DiscUssiOn
Despite studies showing that statins have beneficial effects during 
asthma by decreasing inflammation in the lung, it is unknown 
whether these effects could be mediated by their action on Tregs. 
In this study, by using a murine model of allergic inflammation 
of the airways, we show that ATV treatment leads to a higher 
frequency and phenotypic changes in Tregs, along with high 
IL-10 levels, which could be limiting peribronchial inflammation.
Interestingly, ATV treatment for 7  days increased the 
CD25+FOXP3+ Treg population in lung-draining lymph nodes 
of sensitized animals (Figure  1B), suggesting that lymph 
node–resident conventional CD4+ T cells could be converted 
into Tregs, since conversion to Tregs might be mediated by 
statins as has been reported (17, 33). It is thought that statins are 
repressors of several signaling pathways that negatively regulate 
FOXP3 induction, either by blocking IL-6 signaling (34) or 
inhibiting the negative regulators of TGF-β signaling (33) and/or 
probably by downregulating the expression of methyltransferases 
(35), thus promoting the conversion of conventional CD4+ T 
cells into Tregs. Indeed, in models of autoimmunity (36) and 
delayed hypersensitivity (37), statins induce an increase in the 
Treg population, particularly in lymph nodes, which are niches 
favoring Treg induction (38).
In addition, the increase of TGF-β mRNA expression could 
be involved in statin-mediated changes of the size of the Treg 
population (39) since TGF-β promotes FOXP3 expression via 
Smad-dependent mechanisms (40). Alternatively, changes in 
the migration patterns of Tregs could explain this preferential 
enrichment in lymphoid tissues, because of the modulation 
of chemokines and adhesion molecules by statins (20, 37, 41). 
Remarkably, this Treg accumulation in lymphoid tissue could 
be critical for the establishment and regulation of an efficient 
antigen-specific immune response. In fact, by using a mouse 
model of chronic asthma, Carson et  al. (26) showed that the 
resolution of inflammation is correlated with the accumulation 
of Treg cells in lung-draining hilar lymph nodes. On the basis of 
FigUre 3 | aTV increases forkhead box P3 (Foxp3) and transforming growth factor beta (TGF-β) mrna in Mln and the levels of interleukin-10 (il-10) 
in lung in a murine model of asthma. mRNA expression of (a) Foxp3, (B) TGF-β, (c) IL-10, (D) IDO, (e) IL-12A, and (F) EBI-3 relative to the β-actin 
housekeeping gene was obtained from cell suspension of MLN recovered from non-sensitized (NS●), sensitized (S▲), and sensitized treated with ATV (S + ATV▾) 
mice sacrificed on day 27. (g) Supernatants from cell suspension of lung were obtained from study groups, and the levels of IL-10 were evaluated by ELISA. The 
data are shown as mean ± SD (n = 10–19 mice per group pooled from three independent experiments, *p < 0.05, ***p < 0.001, ****p < 0.0001 Student’s t-test).
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increase of Tregs in MLN, we found an increase of Foxp3 mRNA 
expression in this compartment (Figure  3A), confirming the 
ATV effect on Tregs, as demonstrated in the previous studies of 
murine models of acute inflammation (37, 42). We character-
ized the Treg population by measuring the expression of several 
molecules, such as OX-40, GITR, and PD-1, whose suppressive 
capacities have also been implicated during allergic asthma. 
Interestingly, the treatment with ATV for 7 days did not change 
the Treg phenotype in MLN (Figures 2A–C); however, when it 
was administered for 15 days, there resulted a higher percentage 
of Tregs expressing GITR and PD-1 in the lung (Figures 2D,E), 
suggesting an activation state of these cells, particularly in this 
tissue. Nonetheless, we could not rule out that mononuclear cells 
trapped in blood vessels of lungs could have influenced these 
results since mice were not perfused with PBS. Previously, in both 
humans (43) and murine models of asthma (44), the importance 
of these molecules in attenuating inflammation was reported, 
since patients with severe asthma have a lower frequency of 
Tregs expressing GITR compared with healthy controls (43). We 
hypothesize that these phenotypic changes could be attributable 
to the longer duration of the treatment allowing the upregula-
tion of other genes downstream of Foxp3, such as GITR (45). In 
agreement with these results, we previously found that shorter 
treatments with statins increased Treg frequency, whereas longer 
treatments induced phenotypic changes (15); this could turn on 
regulatory mechanisms to maintain a tight control on the size 
and functions of the Treg population (46) since an imbalance in 
this population could have detrimental effects on infections (47) 
and in tumor immunosurveillance (48). Supporting the effect 
of ATV on Tregs, we also found that naive non-sensitized mice 
treated exhibit higher frequency of Treg in MLN and lung, as well 
as Treg expressing OX-40 and PD-1 in lung, suggesting that ATV 
treatment also modulate their frequency and phenotype in non-
inflammatory conditions (Figure S4 in Supplementary Material).
In addition, ATV did not modify the mRNA expression of IDO 
and IL-35 in MLN (Figures 3D–F), which are molecules capable 
of attenuating the inflammatory process in allergic asthma models 
(49–51); since we only evaluated the transcriptional expression of 
FigUre 4 | effect of atorvastatin (aTV) treatment in the type 2 helper cell (Th2) inflammatory response in a murine model of asthma.  
(a) Bronchoalveolar lavage (BAL) cell count was determined using an hemocytometer by diluting the sample1:2 in trypan blue, whereas (B) eosinophils were 
determined after cytocentrifugation of BAL and staining with Wright by differential cell count using standard morphological criteria in non-sensitized (NS●), sensitized 
(S▲), and sensitized treated with ATV (S + ATV▾) mice sacrificed on day 27. (c) Ovalbumin (OVA)-specific immunoglobulin E in serum and (D) cytokines such as 
interleukin (IL)-4, (e) IL-5, and (F) IL-13 in lung homogenate were measured by ELISA in the study groups. Data are shown as mean ± SD (n = 13–17 mice per 
group pooled from three independent experiments, *p < 0.05, ***p < 0.001, ****p < 0.0001 Student’s t-test). ND: not detected.
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such factors, we do not rule out the possibility that these cytokines 
could be increased at the protein level.
The effect of ATV on the suppressive function of Tregs appears 
more controversial (16, 17, 52, 53): we as well as others did not 
observe that statins increased the suppressive activity of Tregs 
(Figure 2F; Figure S6 in Supplementary Material). Thus, at least 
in the times we evaluated and in a non-antigen-specific manner, 
the phenotype observed did not confer a functional advantage 
for Tregs.
Interleukin-10 produced by Tregs constitutes one of the main 
suppression mechanisms during asthma (29). Interestingly, 
ATV treatment further significantly increased the levels of IL-10 
induced by sensitization in the lung (Figure 3G) that was posi-
tively correlated with Tregs in MLN (Figure 6D), suggesting that 
in our model one of the main IL-10-producing cells could be Treg. 
However, we cannot exclude the contribution of other regulatory 
cells with the capacity to produce IL-10, such as Tr1 cells and M2 
macrophages, considering that these cell populations can also be 
modulated by statins (30, 31). The importance of these findings 
is based on the fact that patients with asthma produce less IL-10, 
suggesting the fundamental role of the cytokine as mediator of 
immunological tolerance in the airways (54). Both ATV (55) and 
CD25+FOXP3+ Treg-producing IL-10 have been associated with 
decreases in the Th2-type allergen-specific immune responses in 
the airways (29). However, we observed no reduction of the Th2 
response (Figure 4), probably because i.n. OVA administration 
leads to increased exposure and absorption of the antigen in 
the lungs, causing a higher intensity of inflammatory response 
compared to the aerosolized challenge (56). Likewise, regardless 
of ATV treatment, this high grade of inflammation could also 
explain why Tcon proliferation was not further suppressed by 
Tregs from ATV-treated mice, considering also that the upregula-
tion of GITR and OX-40 on Tcon (Figure S5 in Supplementary 
Material) can confer to them resistance to suppression by Tregs 
(57, 58) and also the expression of these molecules maintains the 
Th2 inflammatory response (59, 60).
In contrast to the generalized inflammation observed in 
BAL, a more detailed analysis of lung tissue revealed that ATV 
treatment significantly reduces the accumulation of eosinophils 
and lymphocytes in peribronchial regions induced by sensi-
tization (Figures  5A,B). Furthermore, a negative correlation 
between MLN-Treg and peribronchial inflammation was noted 
(Figure 6A), suggesting an important role of lymphoid nodules 
in controlling the effector phase of allergic asthma, as reported 
(26). Likewise, since ATV reduced the levels of IL-4 and IL-13 
mRNA in lymph nodes (Figures 5E–G) and since IL-13 mRNA 
positively correlated with peribronchial inflammation (data not 
shown), Tregs possibly control the differentiation of effector T 
cells in these tissues rather than inhibiting T cell proliferation. 
Unfortunately, we cannot measure hyperresponsiveness, an 
important parameter in experimental asthma; however, it is 
important to note that ATV, through Treg-independent mecha-
nisms, also decreases hyperresponsiveness and remodeling of the 
airways (55).
Previous researches have demonstrated that another statin 
like simvastatin and rosuvastatin reduce the majority of inflam-
matory markers (eosinophils in BALF, type 2 cytokines in lung, 
OVA-IgE in serum, and mucus production) and that ATV only 
modulates the inflammation when it is administrated from the 
beginning of sensitization phase until end of the OVA challenges 
(61). Therefore, the discrepancies between our results and these 
findings could be due to differences in pharmacokinetics among 
FigUre 5 | atorvastatin (aTV) modulates the inflammatory process in situ in a murine model of asthma. (a) A representative hematoxylin and eosin 
section from non-sensitized (NS●), sensitized (S▲), and sensitized treated with ATV (S + ATV▾) mice showing peribronchial inflammatory infiltrates after 7 days of 
ATV treatment; magnification (×40) and box (×400), the arrows indicate the peribronchial region. (B) Score of peribronchial inflammation was measured on day 7 or 
15 of ATV treatment using the scale described in Section “Materials and Methods.” The data are shown as median and interquartile range of n = 5–8 mice per group 
from one experiment. **p < 0.01, ***p < 0.001 (Mann–Whitney test). (c) A representative Periodic acid–Schiff staining section from each study group showing 
mucus production after 7 days of ATV treatment; magnification (×40) and box (×400), the arrows indicate the mucus in the lumen of the bronchus. (D) Score of 
mucus production was measured on day 7 of ATV treatment using the scale described in Section “Materials and Methods.” mRNA expression of (e) interleukin 
(IL)-4, (F) IL-13, and (g) IL-5, relative to the β-actin housekeeping gene was obtained from cell suspension of mediastinal lymph nodes in the study groups. Data 
from (D,e) are shown as mean ± SD (n = 5–12 mice per group pooled from three independent experiments, **p < 0.01 Student’s t-test).
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the statins used or to differences in the scheme of the treatment 
(number of doses, administration routes, concentration, and 
prophylactic or therapeutic administration of the drug) (19, 21, 
55, 61). In summary, our data support an immunomodulatory 
role of statins mediated by their effect on Tregs in the context of 
allergic asthma. Treg accumulation in lung-draining lymph nodes 
could result from preferential presentation of OVA in lymphoid 
tissues rather than in non-lymphoid organs, such as the lung. In 
addition, Treg location in the target tissue enables them to secrete 
IL-10 and reduce peribronchial inflammation, and on the basis 
of the results obtained in this study, we propose a model shown 
in Figure S7 in Supplementary Material. These results suggest 
that ATV has an immunomodulatory role during allergic asthma 
possibly mediated by Tregs, since a negative correlation between 
the frequency of Tregs and peribronchial airway inflammation 
was found. However, further studies are necessary to deeply 
FigUre 6 | The induction of regulatory mechanisms by atorvastatin (aTV) are correlated with the decrease of peribronchial inflammation in a murine 
model of asthma. Peribronchial inflammation was negatively correlated with (a) CD4+CD25+FOXP3+ cell frequency in mediastinal lymph nodes (MLN), (B) CD4+ 
CD25+FOXP3+GITR+ cell frequency in MLN, and (c) interleukin (IL)-10 levels in the lung, whereas (D) IL-10 levels in the lung were positively correlated with 
CD4+CD25+FOXP3+ cell frequency in MLN. Correlation analysis was determined by Spearman’s correlation coefficient; n = 5–6 mice per group. Sensitized mice: ▲ 
and ATV-treated mice: ▾.
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characterize the airway infiltrate and the molecular mechanisms 
involved in inflammation resolution after ATV treatment.
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